Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2009

01.11.2009

Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study

verfasst von: Frederick A. Spencer, Cathy Emery, Samuel W. Joffe, Luigi Pacifico, Darleen Lessard, George Reed, Joel M. Gore, Robert J. Goldberg

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

While there have been advances in prophylaxis and management of venous thromboembolism (VTE), there are a dearth of data from the perspective of a community-wide study, on the epidemiology, management, and outcomes of patients with a first episode of deep vein thrombosis (DVT) or pulmonary embolism (PE). The purpose of this population-based observational study was to describe trends in the incidence rates, clinical profile, management, and outcomes for patients with VTE. The medical records of Worcester (MA) metropolitan area residents with ICD-9 codes consistent with possible VTE during 1999, 2001, and 2003 were independently validated and reviewed by trained abstractors. A total of 1,567 persons with first-time VTE were identified. Incidence rates (per 100,000) of VTE were stable between 1999 (109) and 2003 (117). A considerable proportion of patients treated for VTE had events of unclear clinical significance (e.g., isolated calf DVT, unconfirmed “possible” PE). By 2003, low-molecular-weight heparin was increasingly utilized as acute therapy and more than 25% of patients with VTE were managed as outpatients. Cumulative rates of recurrent VTE and major bleeding following initial VTE were high (~16% and 12%, respectively, mean follow-up 1,216 days) and did not change significantly between 1999 and 2003. Our data suggest that while the incidence rates of VTE remain high, and outcomes suboptimal, there have been marked changes in its management. Whether these changes will result in future declines in VTE incidence and/or improved outcomes in the community setting will require further surveillance.
Literatur
3.
Zurück zum Zitat Anderson FA, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 151:933–938CrossRefPubMed Anderson FA, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 151:933–938CrossRefPubMed
4.
Zurück zum Zitat Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 158:585–593CrossRefPubMed Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 158:585–593CrossRefPubMed
5.
Zurück zum Zitat Heit JA (2005) Venous thromboembolism: disease burdens, outcomes, and risk factors. J Haemost Thromb 3:1611–1617CrossRef Heit JA (2005) Venous thromboembolism: disease burdens, outcomes, and risk factors. J Haemost Thromb 3:1611–1617CrossRef
6.
Zurück zum Zitat Spencer FA, Emery C, Lessard D et al (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727CrossRefPubMed Spencer FA, Emery C, Lessard D et al (2006) The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21:722–727CrossRefPubMed
7.
Zurück zum Zitat Spencer FA, Lessard D, Emery C et al (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475CrossRefPubMed Spencer FA, Lessard D, Emery C et al (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475CrossRefPubMed
8.
Zurück zum Zitat Spencer FA, Gore JM, Lessard D et al (2008) Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester venous thromboembolism study. Arch Intern Med 168:425–430CrossRefPubMed Spencer FA, Gore JM, Lessard D et al (2008) Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester venous thromboembolism study. Arch Intern Med 168:425–430CrossRefPubMed
9.
Zurück zum Zitat Oger E, EPI-GETBO Study Group (2000) Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 83:657–660PubMed Oger E, EPI-GETBO Study Group (2000) Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 83:657–660PubMed
10.
Zurück zum Zitat Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:401–428CrossRef Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:401–428CrossRef
11.
Zurück zum Zitat Kearon C, Julian JA, Newman TE, Ginsberg JS (1998) Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med 128:663–677PubMed Kearon C, Julian JA, Newman TE, Ginsberg JS (1998) Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med 128:663–677PubMed
12.
Zurück zum Zitat Kakkar VV, Howe CT, Flanc C, Clarke MB (1969) Natural history of postoperative deep-vein thrombosis. Lancet 2:230–232CrossRefPubMed Kakkar VV, Howe CT, Flanc C, Clarke MB (1969) Natural history of postoperative deep-vein thrombosis. Lancet 2:230–232CrossRefPubMed
13.
Zurück zum Zitat Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H (2006) Clinical relevance of distal deep vein thrombosis: review of literature data. Thromb Haemost 95:56–64PubMed Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H (2006) Clinical relevance of distal deep vein thrombosis: review of literature data. Thromb Haemost 95:56–64PubMed
14.
Zurück zum Zitat Kearon C (1998) Diagnosis of a first episode of deep vein thrombosis. In: Ginsberg JS, Kearon C, Hirsh J (eds) Critical decisions in thrombosis and hemostasis. B.C. Decker Inc, Hamilton, Ontario, pp 22–26 Kearon C (1998) Diagnosis of a first episode of deep vein thrombosis. In: Ginsberg JS, Kearon C, Hirsh J (eds) Critical decisions in thrombosis and hemostasis. B.C. Decker Inc, Hamilton, Ontario, pp 22–26
15.
Zurück zum Zitat Hull RD, Raskob GE, Pineo GF et al (1992) Subcutaneous low-molecular-weight heparin compared with continuos intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975–983PubMed Hull RD, Raskob GE, Pineo GF et al (1992) Subcutaneous low-molecular-weight heparin compared with continuos intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975–983PubMed
16.
Zurück zum Zitat Prandoni P, Lensing AW, Buller HR et al (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:411–415CrossRef Prandoni P, Lensing AW, Buller HR et al (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:411–415CrossRef
17.
Zurück zum Zitat Levine M, Gent M, Hirsh J et al (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677–681CrossRefPubMed Levine M, Gent M, Hirsh J et al (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677–681CrossRefPubMed
18.
Zurück zum Zitat Fiessinger JN, Huisman MV, Davidson BL et al (2005) THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 293:681–689CrossRefPubMed Fiessinger JN, Huisman MV, Davidson BL et al (2005) THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 293:681–689CrossRefPubMed
19.
Zurück zum Zitat Buller HR, Davidson BL, Decousus H et al (2004) Matisse Investigators. Fondaparinox or enoxaparin for the initial treatment of symptomatic deep vein thrombosis. A randomized trial. Ann Intern Med 140:867–873PubMed Buller HR, Davidson BL, Decousus H et al (2004) Matisse Investigators. Fondaparinox or enoxaparin for the initial treatment of symptomatic deep vein thrombosis. A randomized trial. Ann Intern Med 140:867–873PubMed
20.
Zurück zum Zitat Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMed Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMed
21.
Zurück zum Zitat Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639CrossRefPubMed Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639CrossRefPubMed
Metadaten
Titel
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study
verfasst von
Frederick A. Spencer
Cathy Emery
Samuel W. Joffe
Luigi Pacifico
Darleen Lessard
George Reed
Joel M. Gore
Robert J. Goldberg
Publikationsdatum
01.11.2009
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2009
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-009-0378-3

Weitere Artikel der Ausgabe 4/2009

Journal of Thrombosis and Thrombolysis 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.